Pre-Procedure Requirements for Anticoagulation in Left Heart Catheterization
For left heart catheterization (LHC), you need to assess bleeding risk, ensure adequate renal function, verify hemodynamic stability, and confirm chest tube drainage is <50 mL/hour before initiating anticoagulation. The standard approach is to start unfractionated heparin (UFH) 12-24 hours post-procedure once bleeding risk is controlled 1.
Key Pre-Procedure Assessments
Bleeding Risk Evaluation
- Verify chest tube output <50 mL/hour over a 2-3 hour period before starting anticoagulation 1
- Assess baseline hemoglobin and platelet count
- Evaluate for active bleeding sources or recent hemorrhage
- Review patient's bleeding history and concurrent medications (particularly NSAIDs, which increase bleeding risk in anticoagulated patients) 2
Renal Function Assessment
This is critical because it determines which anticoagulant you can safely use:
- Calculate estimated glomerular filtration rate (eGFR)
- If eGFR <30 mL/min: enoxaparin, fondaparinux, and bivalirudin are contraindicated 3
- If severe renal dysfunction present: UFH is your only safe option 3
- Adjust dosing of renally cleared medications accordingly 4
Hemodynamic Stability
- Confirm stable blood pressure and heart rate
- Ensure no signs of cardiogenic shock requiring immediate intervention
- Verify adequate cardiac output
Contrast-Induced AKI Risk
- Assess risk factors: advanced age, chronic kidney disease, congestive heart failure, diabetes 4
- Ensure adequate pre-procedural hydration 4
- Plan to minimize contrast volume if eGFR <60 mL/min 4
Anticoagulation Initiation Protocol
Standard UFH Approach (Most Common)
Start 12-24 hours post-procedure when chest tube drainage <50 mL/hour 1:
- Initial phase (first 24 hours): Begin with reduced-dose heparin
- Titration phase (24-72 hours): Gradually increase to full therapeutic levels over next 48 hours 1
- Monitoring: Use activated partial thromboplastin time (aPTT) targeting 1.5-2 times control value 5
Alternative monitoring approach: Activated clotting time (ACT) >200 seconds is standard, though 250-300 seconds may be needed for high thrombosis risk procedures 6
Alternative Anticoagulants (Based on Clinical Context)
Enoxaparin:
- Superior to UFH when treatment duration ≥48-72 hours 3
- Contraindicated if eGFR <30 mL/min 3
- Not recommended if catheterization planned within 22 hours (increased bleeding without efficacy benefit) 3
Fondaparinux:
- Safer than enoxaparin when creatinine ≥265 μmol/L or eGFR ≤30 mL/min 3
- Associated with reduced bleeding and mortality compared to enoxaparin 3
Bivalirudin:
- Reserved for use in the catheterization laboratory during PCI in Canada 3
- Not cost-effective for >24 hour pre-catheterization anticoagulation 3
Critical Contraindications
Do not start anticoagulation if:
- Active uncontrolled bleeding
- Chest tube output >50 mL/hour 1
- Severe thrombocytopenia
- Recent intracranial hemorrhage
- Hemodynamic instability requiring immediate catheterization
Special Considerations
Patients Already on Chronic Anticoagulation
- If on warfarin: Check INR; target 2.0-3.0 for most indications 5
- If therapeutic INR present: May proceed directly to catheterization via radial approach to minimize bleeding risk 7
- If subtherapeutic: Bridge with UFH as above
Timing Considerations
- Elective procedures: Can safely delay 24-72 hours to optimize anticoagulation 3
- High-risk patients (GRACE score >141): Consider earlier catheterization (median 16 hours) with appropriate anticoagulation 3
- Hemodynamically unstable: Proceed immediately without delay for anticoagulation 5
Common Pitfalls to Avoid
- Starting full-dose heparin too early when chest tubes still draining significantly—this dramatically increases bleeding risk
- Using enoxaparin in renal dysfunction—no safety data supports dose adjustment; use UFH instead 3
- Failing to assess renal function—this is mandatory before selecting anticoagulant 4
- Switching anticoagulants mid-course—in SYNERGY trial, two-thirds of patients switched agents with worse outcomes 3